{"result": {"id": "713525e6-1299-40f2-85b9-05f48c122c69", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ARTERIOSCLEROSIS<|>ORGANIZATION<|>Arteriosclerosis is a leading cause of renal artery stenosis, accounting for 82% of cases in China, which can lead to renovascular hypertension.\")\n##\n(\"entity\"<|>LARGE ARTERY VASCULITIS<|>ORGANIZATION<|>Large artery vasculitis (including conditions like Takayasu arteritis) accounts for 12% of renal artery stenosis cases in China, contributing to renovascular hypertension.\")\n##\n(\"entity\"<|>NUTCRACKER SYNDROME<|>ORGANIZATION<|>Nutcracker syndrome is a vascular compression condition that may lead to hematuria and proteinuria, with potential to cause secondary hypertension in later stages.\")\n##\n(\"entity\"<|>RENAL ARTERY STENOSIS<|>EVENT<|>Renal artery stenosis is the primary cause of renovascular hypertension, occurring in 3-5% of hypertensive patients, with major causes being atherosclerosis and FMD.\")\n##\n(\"entity\"<|>MALIGNANT HYPERTENSION<|>EVENT<|>Malignant hypertension is a severe form of high blood pressure that can be associated with renal artery stenosis and requires urgent medical intervention.\")\n##\n(\"entity\"<|>HYPERTENSION WITH HYPOKALEMIA<|>EVENT<|>Hypertension with hypokalemia is a clinical clue suggesting possible secondary hypertension due to renal artery stenosis or other endocrine causes.\")\n##\n(\"relationship\"<|>ARTERIOSCLEROSIS<|>RENAL ARTERY STENOSIS<|>Arteriosclerosis is the predominant cause (82%) of renal artery stenosis in China.<|>9)\n##\n(\"relationship\"<|>LARGE ARTERY VASCULITIS<|>RENAL ARTERY STENOSIS<|>Large artery vasculitis accounts for 12% of renal artery stenosis cases in China.<|>8)\n##\n(\"relationship\"<|>NUTCRACKER SYNDROME<|>RENOVASCULAR HYPERTENSION<|>Nutcracker syndrome may potentially contribute to renovascular hypertension in advanced cases.<|>5)\n##\n(\"relationship\"<|>RENAL ARTERY STENOSIS<|>RENOVASCULAR HYPERTENSION<|>Renal artery stenosis is the direct cause of renovascular hypertension.<|>10)\n##\n(\"relationship\"<|>MALIGNANT HYPERTENSION<|>RENOVASCULAR HYPERTENSION<|>Malignant hypertension can be a severe manifestation of renovascular hypertension.<|>7)\n##\n(\"relationship\"<|>HYPERTENSION WITH HYPOKALEMIA<|>RENOVASCULAR HYPERTENSION<|>Hypertension with hypokalemia is a clinical indicator of possible renovascular hypertension.<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558791, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 635, "prompt_tokens": 3100, "total_tokens": 3735, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3008}, "prompt_cache_hit_tokens": 3008, "prompt_cache_miss_tokens": 92}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 素依赖性高血压。\n　　　肾实质性高血压患者的治疗除了针对原发病的治  疗 ,如使用糖皮质激素及免疫抑制剂等 ,降压治疗也是  重要的一环 ,可以延缓肾脏病进展 ,减少心血管事件。 肾实质性高血压患者启动降压治疗时机及目标血压依  据是否合并蛋白尿而不同(具体参见“8.6 高血压合并  肾脏疾病”) 。常用的降压药都可以用于肾实质性高血  压患者的降压治疗 。其中 ,RAS抑制剂还可以通过非  血压依赖的机制 ,起到降低蛋白尿 ,保护肾脏等靶器官  的作用 ,常优先选用[592] 。非药物治疗中强调饮食限  盐 ,可直接对肾实质性高血压患者起到降压作用 ,并有  助于强化 RAS抑制剂降压及降蛋白尿效果 。 目前推  荐肾实质性高血压患者饮食盐(氯化 钠) 摄 入 量 <  6 g/d(钠<2.3 g/d或<100 mmol/d)[681] 。严格限盐  初期 , 肾功能减退患者可能因肾脏不能很快地减少钠  的排泄而出现钠的负平衡 ,使细胞外容量明显减低 ,导  致肾前性急性肾损伤 ,应注意监测。\n\n\n10.2   肾血管性高血压及其他血管病引起的高血压\n　10.2.1   肾血管性高血压   肾血管性高血压是常见的  继发性高血压之一 ,为肾脏血流灌注不足而导致的体  循环血压升高 。主要病因是肾动脉狭窄 , 占高血压人  群的 3%~ 5% ;此外 ,也不能忽视其他少见的肾血管  性高血压病因 ,如肾动脉栓塞、肾动脉瘤、肾动静脉瘘、 腹主动脉夹层累及、肾(外)肿瘤压迫、先天性肾动脉发  育异常等 。在我国 ,动脉粥样硬化是导致肾动脉狭窄  的主要原因 ,约占 82% ,大动脉炎约占 12% ,纤维肌性  发育不良(fibromusculardysplasia,FMD) 及其他约占  6% 。 肾静脉受压 , 比如胡桃夹综合征 ,是否会导致肾  血管性高血压 , 目前尚有争议 。一般认为早期主要表  现为血尿、蛋白尿 , 后期可能影响肾功能 , 导致血压  升高。\n　10.2.1.1   诊 断 评 估     临 床 线 索 : ① 30 岁 以 前 或 55岁以后发生的高血压 ;难治性高血压 ;恶性高血压 ; 高血压伴低血钾 。②不 明原因的肾功能衰竭 ; 服用 ACEI/ARB治疗后肾功能恶化 ;一侧肾脏萎缩或两侧 肾脏长径相差 1.5 cm 以上\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>RAS INHIBITORS<|>ORGANIZATION<|>RAS inhibitors are medications used to treat hypertension, particularly in patients with kidney disease, by reducing proteinuria and protecting target organs like the kidneys through non-blood pressure-dependent mechanisms. They are often prioritized in treatment plans for renal parenchymal hypertension.\")\n##\n(\"entity\"<|>ACEI/ARB<|>ORGANIZATION<|>ACEI/ARB refers to a class of drugs (Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers) used in the treatment of hypertension, especially in cases involving kidney disease. These drugs can sometimes cause renal function deterioration in certain patients.\")\n##\n(\"entity\"<|>FIBROMUSCULAR DYSPLASIA (FMD)<|>ORGANIZATION<|>Fibromuscular Dysplasia (FMD) is a vascular condition that can cause renal artery stenosis, leading to secondary hypertension. It accounts for a small percentage of renal artery stenosis cases, with atherosclerosis being the more common cause.\")\n##\n(\"entity\"<|>HYPERTENSION<|>EVENT<|>Hypertension is a chronic medical condition characterized by elevated blood pressure. It can be primary or secondary, with secondary hypertension often linked to underlying conditions like kidney disease or renal artery stenosis.\")\n##\n(\"entity\"<|>RENAL PARENCHYMAL HYPERTENSION<|>EVENT<|>Renal parenchymal hypertension is a type of secondary hypertension caused by kidney disease. Treatment involves addressing the underlying kidney condition and managing blood pressure to slow disease progression and reduce cardiovascular events.\")\n##\n(\"entity\"<|>RENOVASCULAR HYPERTENSION<|>EVENT<|>Renovascular hypertension is a form of secondary hypertension resulting from reduced kidney blood flow, often due to renal artery stenosis. It accounts for 3-5% of hypertension cases and can be caused by atherosclerosis, FMD, or other vascular abnormalities.\")\n##\n(\"relationship\"<|>RAS INHIBITORS<|>RENAL PARENCHYMAL HYPERTENSION<|>RAS inhibitors are used to treat renal parenchymal hypertension by reducing proteinuria and protecting the kidneys.<|>8)\n##\n(\"relationship\"<|>ACEI/ARB<|>RENOVASCULAR HYPERTENSION<|>ACEI/ARB drugs are used in the treatment of renovascular hypertension but can worsen renal function in some cases.<|>7)\n##\n(\"relationship\"<|>FIBROMUSCULAR DYSPLASIA (FMD)<|>RENOVASCULAR HYPERTENSION<|>FMD is a cause of renovascular hypertension due to renal artery stenosis.<|>6)\n##\n(\"relationship\"<|>HYPERTENSION<|>RENAL PARENCHYMAL HYPERTENSION<|>Renal parenchymal hypertension is a subtype of hypertension caused by kidney disease.<|>9)\n##\n(\"relationship\"<|>HYPERTENSION<|>RENOVASCULAR HYPERTENSION<|>Renovascular hypertension is a subtype of hypertension caused by renal artery stenosis or other vascular issues.<|>9)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_0455b184df244a60a91558e78deb504a049013061f2942892b46d01144040cd3_v2"}